DadFinStart your free week
DadFin › Stocks › Healthcare › QTTB

Q32 Bio Inc. (QTTB) stock score

Healthcare · Biotechnology · United States

$8.34 ▲ +3.09% today

45.4
Dad Score, out of 100
middling

Q32 Bio Inc. (QTTB) is a Biotechnology company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 45.4 out of 100 on the Dad Score, a middling reading that places the business ahead of 45% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #463 of 974. Its strongest axes are valuation, quality and risk; its weakest are growth and price action.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Above average
Quality
Strong
Growth
Below average
Price action
Weak
Risk
Strong
Conviction
Above average
Liquidity
Above average
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)2.6×
P/E (forward)-8.1×
Dividend yield0.00%
Return on capital61.3%
Operating margin39.9%
Revenue growth (YoY)+0.0%
FCF yield-16.2%
Net debt / EBITDA-4.63×
Piotroski F-Score4 / 9
52-week change+279.3%
Market cap$245M
Next earnings—

What subscribers see on QTTB

Start your free weekSubscriber? Open the full research →

Biotechnology peers

StockCompanyDad ScoreBandMarket cap
VRTXVertex Pharmaceuticals Incorporate51.2middling$127.8B
MRNAModerna, Inc.23.4weak$75.9B
REGNRegeneron Pharmaceuticals, Inc.91.1strong$75.7B
ARGXargenx SE55.1middling$57.5B
RVMDRevolution Medicines, Inc.40.6middling$44.3B
ONCBeOne Medicines AG94.5strong$40.7B
RPRXRoyalty Pharma plc70.8good$33.0B
ALNYAlnylam Pharmaceuticals, Inc.83.8good$29.4B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.